丁苯酞软胶囊对早期老年性帕金森病的疗效观察

Observation on Effect of Butylphthalide Soft Capsule on Early Senile Parkinson's Disease

目的:探讨丁苯酞软胶囊对早期老年性帕金森病(PD)患者的临床疗效并通过血清学指标的变化分析其可能的作用机制.方法:选择2017年1月至2018年12月82例P D患者,按随机数字表将分为对照组和观察组,各41例.两组患者均给予多巴胺能药物,观察组在此基础联合丁苯酞软胶囊口服,治疗周期为12周.治疗前后采用Hoehn&Yahr分级(H-Y分级)、新版世界运动障碍学会帕金森病综合评量表(MDS-UPDRS)第1部分、第3部分评价临床疗效,同时检测血清中超氧化物歧化酶(SOD)活性、丙二醛(MDA)、白细胞介素6(IL-6)、神经元特异性烯醇化酶(NSE)水平.结果:观察组帕金森病患者治疗后MDS-UP DRS-1评分、MDS-UP DRS-3评分和H-Y分级低于对照组,对照组治疗后SOD、MDA、IL-6、NSE有不同程度改善,而观察组治疗后的SOD活性较治疗前显著上升,MDA、IL-6、NSE较治疗前明显下降,差异有统计学意义,P<0.05.结论:丁苯酞软胶囊联合多巴胺能药物可降低早期老年P D患者H-Y分级、MDS-UP DRP S-1、MDS-UP DRS-3评分,改善SOD、MDA、IL-6、NSE水平,改善疾病预后.

Objective:To investigate the clinical efficacy of butylphthalide soft capsule in the treatment of early senile Parkinson's disease(PD)and analyze its possible mechanism through the change of serological indexes.Methods:82 PD patients from January 2017 to December 2018 were selected and divided into control group and observation group according to the random number table,41 cases each.Two groups of patients were given dopaminergic drugs,the observation group on this basis combined with soft capsules of butylphthalide oral,the treatment cycle was 12 weeks.Before and after treatment,Hoehn&Yahr classification(H-Y classification)and mds-updrs(Part 1 and Part 3)were used to evaluate the clinical efficacy.Meanwhile,the activities of superoxide dismutase(SOD),malondialdehyde(MDA),interleukin-6(IL-6)and neuron specific enolase(NSE)were measured.Results:The MDS-UPDRS-1,MDS-UPDRS-3,and HY scores of Parkinson's disease patients in the observation group after treatment were lower than those in the control group.After treatment in the control group,their SOD,MDA,Both IL-6 and NSE improved in different degrees.After treatment,their SOD activity in the observation group increased significantly compared with that before treatment,and their MDA,IL-6,and NSE significantly decreased compared with before treatment.The difference was statistically significant(P<0.05).Conclusion:The Butylphthalide soft capsules combined with Dopaminergic drugs can reduce the H-Y grade,MDS-UPDRS-1,MDS-UPDRS-3 scores of early PD patients,improve their SOD,MDA,IL-6,NSE levels,and improve the prognosis of patients with PD.